Drug Discovery

Regulatory bodies like the FDA will likely demand more detailed pharmacokinetic characterization of tissue distribution following the prolonged activity seen with Kylo-11. The cardiovascular research community is currently absorbing the profound implications of the Phase 1 clinical trial results

While complex genetic clusters were once thought to be the key to precision medicine, new analysis suggests that routine clinical data may be just as effective for drug selection. For decades, the management of Type 2 diabetes has relied on a rigid, standardized protocol where patients are moved

The interdisciplinary collaboration between biology and chemistry labs is essential for synthesizing new molecules capable of tagging cancer-essential proteins for destruction within the cell. This scientific synergy is particularly vital in the context of pediatric oncology, where the biological

Phase I Pharmacokinetic studies cannot reach their primary endpoints until bioanalytical data is confirmed as valid across the newly integrated organizational framework. The clinical research landscape shifted significantly with the announcement of Fortrea’s acquisition of Worldwide Clinical

The PandaOmics platform processes massive biological datasets, including gene expression and scientific literature, to uncover therapeutic applications that human researchers often overlook. In the current landscape of 2026, the pharmaceutical industry has transitioned from speculative

When the protein-processing machinery of the endoplasmic reticulum is overwhelmed by external stressors, it triggers a cascade of signaling pathways that culminate in programmed cell death. In the current landscape of 2026, oncology has moved decisively toward these types of organelle-specific